Clinical trial
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
NCT03649477 is registered in ClinicalTrials.gov with Levo Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
- Lead sponsor
- Levo Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 20, 2018
- Completion date
- July 9, 2022
- Enrollment
- 130 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.